摘要
目的 探讨米非司酮对子宫肌瘤组织内雌、孕激素受体和表皮生长因子受体的影响。方法 44例子宫肌瘤患者作全子宫切除或子宫肌瘤挖出术 ,其中米非司酮组 16例 ,术前予米非司酮 2 5mg ,每日 2次 ,连用 3个月 ;对照组 2 8例。采用免疫组化法测定子宫肌瘤及子宫平滑肌内雌、孕激素受体含量 ,用流式细胞仪测定EGF -R水平。结果 米非司酮组子宫肌瘤及子宫平滑肌内PR较对照组显著下降 (P <0 0 1) ,ER无显著差异 ;米非司酮组子宫肌瘤及子宫平滑肌EGF -R水平显著低于对照组 (P <0 0 1)。结论 子宫肌瘤内EGF -R减少是米非司酮治疗后子宫肌瘤缩小的重要机制 ,这一作用可能与米非司酮阻断孕酮与PR的结合有关。
Objective To study the effects of mifipristone on estrogen receptor(ER),progesterone receptor(PR) and epidermal growth factor-receptor (EGF-R) in uterine leiomyoma.Methods Hysterectomy was performed in 44 patients with leiomyoma who were divided into study group(16 cases)that were administrated with mifipristone 25mg,twice a day for 3 months before operation, and control group(28 cases)that did not receive mifipristone.RE?PR and EGF-R level in leiomyoma and myometrium of two groups were determined respectively by immunochemistry and flow cytometry.Results PR and EGF-R level in leiomyoma and myometrium of study group significantly decreased compared with that of control group(P<0.01),there was no significant difference in ER between two groups.Conclusion The decrease of EGF-R in leiomyoma may be one of the important mechanisms of leiomyoma regression after treatment with mifipristone;this may be related with mifipristone that blocks the combination of progesterone with PR.
出处
《中国实用妇科与产科杂志》
CAS
CSCD
北大核心
2002年第1期30-32,共3页
Chinese Journal of Practical Gynecology and Obstetrics
关键词
子宫平滑肌瘤
此激素受体
孕激素受体
米非司酮
表皮生长因子受体
Uterine leiomyoma Estrogen receptor Progesterone receptor Mifipristone Epidermal growth factor-receptor
